Charity regisiration number.. 1198095 Compan}. registrdtion number= CE028473 AMMF - The Cholangiocarcinoma Charity (A Charitable Incorporated Ihganisationl Annual Report and Financial Staiemen for ihe Year Ended 31 January 2026 Edmund Carr LLP Chartered Ac¢ountsnts & Statutory Auditor 146 New London Road Chelmsford ssex CM? OAW
AMMF - The Cholangiocarcinoma Charity Contents Reference and Administyative Dethils Trustees, Report 210 11 Independent Examinerfs Report Statement of Financial Activities 13 Balance Sheet 14 Stat¢mcn¢ of Cash Flows 15 Not¢5 to th¢ Financial Stat¢rn¢nts 16to25
AMMF - The Cholangiocarcinoma Charity Referenee and Administrative Details Chairma Mr Noel Corrigan Tru5tee5 Mrs Gillian C(wrigan Mr Harold Corrigan Mr Tom Morement Senior Man3gernent l Leadership Mrs Helen Morement. CEO Registered Office Enterprise House BossingtrA)um Road Siansied CM24 IQW The charily is ineorporaied in England and Wales. 1198095 Ch8rily Rt%istr&tion Number Company Registration Number CEO?8473 Independen¢ Exarniner Edmund Carr LLP Chartered Accounianis & Stsiutory Auditor 146 Ncw. l.ondon Road Chelmsford CM? OAW Page I
AMMF - The Cholangiocarcinoma Charity Trustees, Report The trustees present iheir rewn wilh the financial sthiemenis of ihe chariiy (or ihe year ended 31 January 2026. The irusiees have adopied the provisions of Ateouniing and Repy)rting by Chariiies.. Sthiement of Recommended Practice applicable to thaiilies pieparing their accounts in accordance with ihe Financial Reporting Standard applicable in the UK and Republic or Ireland (FRS 1021 (effeciive l January 20191. AMMF The Cholangiocarcinoma Charity 'as regisiered with ihe Charity Commission as a Charitable Incorporaied Organisaiion (CIO) during ihe year ?0?? The CIO regisiered number '1th the Charity Commission is 1198095. The charity was originally regisiered in ?IM)2 under ihe name. The Alan Moremeni Memorial Fund (working tille. AMMTr l and was an unincoTpofdted charity with the registrntion number 1091915. To support the coniinuing grOlh of the charity. AMMF'S Trnse$ decided that it should transition as a legal entiij. from unincorpordied regISred chariry sraius io ihai of a Charitable Incorporated Organisation ICIO). The new CIO siarus a5 approved on O l June. ?0? Ai ihai poini ihe work and all assets of ihe original chariry passed io the new CIO chariry. The ori&pinal chariry and its registered number 1091915 will always remain in existence, with all records submitted io the Chariiy Commission 5111] available on the Commission's website, but thi5 entity will now remain in thc backuiround. The charity. under its CIO status. is otTicially know'n as.. AMMF- The Cholangiocarcinoma Charity. AMMF 's aims and objeciive5 remain unchangied. and the chariiy's work has conlinued 5eainlessly and without interruption since ihe incepiion of thc CIO on O l June ?0?? Throu&ihoui this document AMMF refers to the CIO. AMMF - The Cholangiocarcinoma Charity. Objectives and actvitie5 AMMF'5 MISSION A world improved for the cholaiigiocarcinoma palieni by the Sharing of knOledge a¢r05s ¢he healthcare and re5¢arch communities and H'ith the family ofaffected people across the globe. AMMF's V1510N A Orld where people liv¢ their lives free of ¢holangiiKwrinoma ICCA) as a lirthreatenillg disease. AMMF the CholangjooalnQrna CharÉty is th¢ only charitv in the UK solely dedicated to holanglar(lma Ibile durt cancer). AMMF works iiationally throughout the UK, as well as iii Europe, and collaborates globally. AMMF 15 wholly committed nationally and internationally to tackling the devastating cancer, cholangiocarcinorna {CCA) on all fronts and. ultirnately. to help find a cure. through.. SLlPPOrt - Providing information to individuals or group5 to support a patient or loved one along their joumey Etnpowemient Empowering patient5 and their loved one5 to advocate for themselves. 5cek better care. new tieatmetlt options and second opinion5 Acce5S Advocating equitable access for patients to ensure they have access to the latest treatment option5 and a tnitlitniitn standard of care appropriate to them Awareness Raising awareness of CCA io supwi earlier diagnosis. fair and equal access to treatments. including rtew treatment approaches
AMMF - The Cholangiocarcinoma Charity Trustees, Report Research - Encouraging and SUPTX)rting research into causes. diagnostics. and treatsnent for those with CCA Policy- Working tow'ards ensuring healih Care p)licies refleci the needs of those with CCA CCA is under-represenied and under-funded across all areas. including policy. services. and research. li is a poorly undersiood and under researched disease 'hiCh is increasing in incidence nL)i only in Ihe UK but Ihroughoui ihe world. Lack of awareness and ihe dilTiculiies of achieving clear and accuraie diagnosis. mean thai mosi are ai an advanced stsge and in0rable ai lime of their diagnosis. Whilst surgery remains ihe only poteniially curative ireatmenL there is now chemoiherapy. tsrgeied Iherapies and immunotherdpy. and a grOlg iiuinber of clinical irials. in panicular those investigating funher iargeted iherapies and immunoiherapies. Ho*'ever. a diagnosis of inoperable CLA remaiiis invariably fatal. and this is a siiuaiion ihai has nor altered in decades. AMMF is committed to working ro change this scenario. naiionally and inrnatIonally. Activities Re501uie in briThging about improvement for the CCA patieni, AMMF conrinues to work closely with patients and ihcir carers. cliniciank healthcare professionals. researchers, and policy makers. a5 well as actively collaboraiin& &plobally. Providing Support And Information AMMF'S CEO and M¢mr5 of ih¢ Ammf team atiended ihe vinual NHS cancer chariiy bTiefin&i meelin&is throughoui •O?5. These regiular m¢¥'iingJs have proved helpful and infonnative, providing dLtai15 of iiew dev¥lopments in NHS processes and policies in a timely manner. AMMI-' s M¢dical and Clinical Advisors are coniacled on a reLiular basis for hllp and advice on ho best io handle the more di1¢Ult palien¢ queries the charil}' receive5, and for upioyla¢e infoThalion oli ¢lini¢al trials. AMMF'5 w'ebsile ¢(Trnlinued io be UF¥lated regularlv. and pn)vtdes infonnati¢)n on all aspects of CCA. including ¢reatments and specialists. th¢ advances being made and. importpntly. there is a coinprehensive list of the ¢linical trials ¢ha¢ are available and recwiling in the UK. which is proving a valuable resource to healihcaTe professionals and palients. MThw.ammf.org.uk The charity us¢s a number of SIKial media platforn15 Facebook. X {fonllerl)' Twitter). Ii)stagram. Linkedln and Blu¢Sky. Th¢s¢ are each kept up to date w'ith daily infomiation of iinportaiice and relevance to SiiPPQrters. Th¢ number of followers on eaoh ¢i)ntinues to grow. with Facebook in particular n(Trw at (Trver 7,000 follow¢rs. AMMF'5 three private. metnber only. 5UPPOrt groups on Facebook. Cholangiocarciiiotna Support- UK and Europe.. for Patients and Carer5. for Patients Only. and for those bereaved. coiitinue to grow. The groups provide an invaluable resource for patients and their loved one5 and. moderated by three knowledgeable volunteer5. each group 15 a safe and private space in which to share information. and to help and 5UPPOrt each other. The requirement from indiyidual patients and family member5 for specific infomiation regarding specialist on5111tants and treatrnentS COlltinue5 to increase. With the wider aM"arene55 of the charity. increasing incidence and 8row.ing recognition of CCA. it i5 anticipated this area of work will continue to expand. Advocating Access During the year 2025. the chariiy Continued its adVa¢Y worL especially in helping those Hith CCA to navigate their way io knowledgeable specialists wherever p)ssible. Page 3
AMMF - The Cholangiocarcinoma Charity Trustees, Report Westrninster Reception - On ?6 FebrnaTV. during ChOlangi(arCinOma A wareness Month. AMMF held a reception at the House of Commons. Wesiminsier. Hosted b) Mar>. Glindon MP. presenthiions There given by AMMF'S CEO Helen Moiement. Kaiie Nicholl. a CCA survivor and n)yal correswndent, and emineni specialist. Professor John Bridgewaier. Each presenter talled for ihose wilh the power to change policy to do so to enable a 'Fairei Deal. Faster, for all diagnosed with CCA. More than iweniy MPS. peers. and iheir researchers and aides. attended ihe eveni. along with representhiives from NHS England. pharmaceuiical companies and e%pen healihcare providers. Holyrood - I l June 2025 On I l June 2075. AMMF i¢Kbk the Reihink Liver Cancer campaign io ihe Scoiiish Parliameni (Holvroodl for ihe first time. calling for a 'Fairer Deal. Fasier, for people diagnosed with CLA in Scotland. AMMF drew atteiition to ne. daia shoM'ing ihe growing number of ihose '1th CLA iii Scotland. and that Scoiiish CCA patients were unable io access full molecular profiling as there a5 funding available for only a single gene fauli. H'hereas ihose in England had access 10 a wider molecular profiling panel. As a result, some Scottish patients were missing opportunities to acces5 NH&approved life-extendin targycted treatments and clinical trials. This creaicd inequity comparcd with Engiland. rcsultingT in some Scottish patients with the means to pay privately accessing iesting and treaunent across ihe border. At thc reccpiion, hosted and introduced by Beli Macpherson MSP for Edinburgh Northern and Leith. prcscntations w'erc givcn by.. J¢nni Minlo MSP, Minister for Public Health and Women's Health Hi.l¥n Morem¢n¢, AMMI.. Chief Executive B¥iijamin Carey. PaiiLni RLpresenthiiVe for NHS Scoiland's HepatoPancrealoBiliary NelwoTk Prol¥ssor Tim Kendall. Personal Chair of Liver Paiholog). at ihe University of Edinburgh and Consuliant Liver Patholo&TiSt at the Royal Infirniary of Edinburgh The reception was att¢nd¢d by five MSPS lincluding ihe Minister) as w¢ll as people with lived experience of CCA from across Scoiland. expert healthcare provid. researchers and phannaceulical coinpany repr¢sen¢alive5. Following the reception. Jenni Minlo MSP (Minisier for Public Heal¢h and Women's Heal¢hl agreed to onsider a hu5iness case for molecular profiling tests for CCA for thos¢ iii Scotlaiid. and to provide a formal response. AMMF liaised with the Scolli5h Hepatobiliory Cancer Network. to develop and submit the busin¢s5 ¢a5¢. As a resiilt of this, in D¢¢emb¢r ?0?5. Jenni Minto MSP announced that the Scottish Government would be SUPPOrting the implementation of the molecular t¢sting prograJnm¢ for CCA. Funding would be released in 20?6 to the NHS Scotland Genomic Laboratorie5 to deliver this Service. The testing programme for CCA was prioritised ahead of w'ider refortns to the 8enornic medicine service. Raising Awarene5$ The Rethink Liver Cancer Campai During ?0?5. AMMF'5 'Rethink Liver Cancer. campaign ontinued. workin8 to broaden tht focus of liver cancel frotn being &Nclusively hepatocellular carcii)oma {HCC} to highlight that CCA i5 also a primary liver cancer. at]d to ra15e awareness and influence health policy foi better recognition. earlier diagn05L5. and equitable treattnet]t acces5. Page 4
AMMF - The Cholangiocarcinoma Charity
Trustees' Report
The 2025 initiative under the campaign was the request for "A Fairer Deal, Faster". To promote this request, a photo shoot, 'Faces of Cholangiocarcinoma' was arranged with the celebrity photographer, Rankin, who waived his f for a day's photography at his studio. Eight people with CCA were involved in this, including Zandra R hodes (designer), Katie Nicholl (royal correspondent), Charlie Shrager (model), and others well known to the charity - Ilona Smith, Andrea Sheardown, Andy Clay, Judith Neptial, Benjamin Carey. The individual portraits formed part of the 'Faces of Cholangiocarcinoma' project, which launched at the start of February's Cholangiocarcinoma Awareness Month, and continued throughout 2025 to raise awareness.
On the day of the shoot, a 'behind the scenes' video was created by Dead Ready, AMMF's video team. AMMF's PR/comms team also recorded individual interviews, and these were used to create a new campaign video, "Rethink Liver Cancer - for a Fairer Deal Faster'' which was shown for the first time at AMMF's Westminster reception on 26 February, 2025. It was also used throughout 2025 at meetings and events where the CEO, Helen Morement was invited to speak.
• The 'Behind the Scenes video: https://www.youtube.com/watch?v[=] vDZ7mrkl86U • The campaign video, "Rethink Liver Cancer for a Fairer Deal Faster'': 9loCFcubudI https:/ /www.youtube.com/watch?v[=]
AMMF's awareness raising work during February 2025, especially around the 'Faces of Cholangiocarcinoma' project, achieved a considerable amount of media coverage over the month:
198 pieces of published/ broadcast media coverage, including:
• 3 x national TV broadcast (BBC Breakfast, ITV Lorraine and GB News Breakfast)
• 5 x regional TV news broadcasts (BBC South-East lunchtime and evening; ITV London breakfast, lunchtime and evening)
• 2 x radio broadcasts (BBC Radio Merseyside and Boom Radio)
• 13 x national newspaper print features / news stories (Daily Mail, Mail on Sunday, The Mirror, Irish Mirror and Northern Ireland Mirror, Daily Express and Irish Daily Express, Scottish Metro, The Herald, The National, The Scotsman, Daily Record and Morning Star)
• 13 x features / news stories on national news websites (MailOnline x 3, The Metro, The Independent, Scotsman, Irish News, The Sun, GB News, BBC Online)
• 5 x print news stories in regional Scottish newspapers.
• 130 x news stories on regional newspaper websites from across the UK.
• 3 x BBC Online news stories (featuring Charlie, Zandra and Helen/ Andrea Sheardown / Sian Ashcroft)
• 19 x news stories on international news websites (including The Mirror USA, msn.com and aol.com)
• 1 x feature on international lifestyle website (vanityfair.com)
The combined audience reach was over 865 million
- HPB Nurse Study Day 07 May 2025 - AMMF's Hepatobiliary (HPB) Nurse Study Day was launched in 2025 to address a need for nurse-led education and networking opportunities to advance clinical practice and improve patient outcomes.
The progra e included current and emerging treatments, prognostic assessments, surgical considerations, clinical trial consent and care, and an international overview of HPB nurse roles and responsibilities. This progra e was approved by the Royal College of Nursing, who gave an accreditation of3.5 hours.
AMMF was grateful to receive fmancial sponsorship for the Nurse Study Day From AstraZeneca and The Access Foundation.
Page 5
AMMF - The Cholangiocarcinoma Charity Trustees, Report AMMF'S EuropeaTh ch0langiocarci0m CoDfereNce 07 - 09 May 2025 was a three•day hybrid event showcasing groundbreaking reseaith. innovative ireaiments. and the eollaboraiive spirii of the CCA community. The chariTh' N'as delighied to elcOMe No iniemaiionallj renOned specialists ai the fL)refront of the CCA 'orld. Ms Rachel Guest (surgeon. Edinburgh) and Dr Hein7-Josef Kjumpen {oncologist. Amsrdam1. as CchaIrS of ihe ?0?5 conference. The). expertly hosied a faculty of 40 internaiional speakers and managed some challenging Q & A sessions. all exploring ihe conference iheme.. "A Fairer Deal. Faster" As in previous years. Ihe conference broughi togeiher a diverse audience. including healthcare profes%ionals IHCPS). researchers. medical siudents. paiieni organisaiions. parients. carers and patient advocaies. This mix provided a unique plaiforn) for exchanging knOledge and per5ctiVeS, enhancing ihe undersianding and management of CCA. Impactful personal perspectives were shared by ihree CCA patients and one carer. Their powerful individual stories hi&Trhlighied real-m'orld challenges including the cNcial Iieed for specialist knowledge. early diagynosi5, comprehensive support sysrems and the im[rf)rnCC of ensurinky equity in diakTnosis and managTcmcnt for all, rcgyardless of who ihey are or where they live. AMMF'S conference was endorsed by the BSC {Briiish Society for the Study of the Liver), and was a CPD accredited event. worth 19.5 hours CPD Iconlinuing Professional Development). AMMF was grateful ¢0 receive financial sponsorship for the eveni from the pharniaceutical organisation5'. Astrazeneca, Jazz Phamiaceulica15. Taiho Oncology Europe. Servier. and Boehringer Ingelheim. The full pro&Tramme and all conference presentalions from the three days ere recorded and reinain available to view via AMMF'S website. See.. hiips-Ilammf.org.uklammfonr¢renc209sI Public Bcnefit IM lomiiti& ¢h¢ charily's (Trbj¢ciives and plonning the a¢tivitie& the Injsiees have considered the Charity Commission's guidance iii r¢sp¢cl of publi¢ benefit. Acheivements and perforrna Trce Supporting Research AMMF. remaiii% conimitted to supporting research inlo CCA. In 20?5. based on the advice of AMMF'S Scientific Advisory Board. awards w¢re offered and ac¢ept¢d by the fourteen instltutions to 5UPPOrt their r¢search into CCA.. AMMF'5 Research Aw2rd$ In ?0?5. aw'ards w'eTe offered and accepted by the follow'ing to 5UPIM)rt their research into CCA.. Vniversitv of Lei¢e$t¢r {Dr Ed Jgrmanl AMMF Ref- 20251227 Re5carch.. Doc5 COX? pattern thc local immune cTri'ironinciit to promote early neopla5tic grow1h? Award.. £50.000 (to be given in two in5talments) Sapienza Universitv of Rome {Dr VeroDiCa Porreca) AMMF Ref - 20251228 Re5eaich.. Targetins the adhesive function5 in inttzhepatic CCA prOg5S1on.. focu5 on the cancer cell surface receptors engaged by the THBSI and THBS? Award.. £40.000 (to be given in two in5talrnents) Henri MoNdor UDiversitY Hospital (Prof JulieD Calderaro) AMMF Ref- 20251229 Research.. AI-CCA.. Artificial Intelligence as a Biomarker for Intrahepatic CCA Page 6
AMMF - The Cholangiocarcinoma Charity Trustees, Report Award.. £44.000 lio be given in insialments) Universitv of Edinburgh {Dr Rachel Guest} AMMF Ref - 20251230 Research." The role ol IDH muiaiion in lil'er cell plasiicil%' and Inirahepatie CCA Award". £97.i48.37 (to be given in insthlmenLsI Wtlleome Sanger Institutt {Dr Ashrav Gunjur) AMMF Rtf - 2025ll31 Researeh.. The immune implications of inird-iumoural bacieria in CCA.. a translational research siudy using samples trom the 'CheckPAC' phase 11 clinical trial Aw'ard.. £16.780.00 (io be given in one insthlmeni) University College London (Prof John Bridgewater) Ref- 20251232 Research.. Integiraiion of SAFIR-ABLIO da inro (he ENS-LCA dabase Award.. £?0.503.ou iio be given in one insthlineni) Universitv ol Birmingham (Mr Kav*ni Kavani) AMMF Rtf - 202V233 Rcsearch.. Siablc fujiciional Induccd Tregjs ISFiTrcgysl.' A iiovcl me}5 of immunosuppression for patients Iransplanted for CCA iii ihe crn of iransplani oncology Award.. £99,317.67 (io be given in one in5talmenl) University of Nottingham (Prof%heela Jai'aramanl AMMF Ref - 202W234 Research.. New approaches for improvLd sicni paicncy and iumour cell killiiig Award.. £75.504.37 (io be gyiven in Ihr¢e instalmenlsl During 2025 the following pa)'ments were made re existing awards: Unii'er5it J. of GlasRow- AMMF ref: 20231218 £49,73•.00 was paid on ?3.03 ?5 rLprLsiniing ¢he second InSlment of the award of £99,464.00 aLireed ¢0 fund the work.. Id¢nlifving iherapeutic opportunities for Biliary Cancers by investigating ihe Tole of Monocytes in dg r¢spons¢. Uni%'crsit)' of Oxford - AMMF Ref: 20231219 £56,00•.57 was paid 011 17.06.70?5. T¢PT¢seiiling full pavment of the award of £56.00? 57 agreed to fund the work.. Normal cholangi(KJle ¢ontainm¢nt of CCA through tn¢thboli¢ and tr)ScrIptoM]C regulatioii Sapienza Universit). of Rome- AMMF Ref: 2022nl I £211.939.06 paid 011 14.11 ?0?5. the s¢coiid athd filial ijistalmenl of award of £35.000.00 for th¢ Ork.. The rol¢ of "fHBSI. THB52 and PE"Dk in the lymphatic dissemination of the intrah¢patic CCA.. identification of downstream signalling S8pienz8 Universit) of Rome- AMMF Ref: 20251228 £20.399.37 wa5 paid on l? l ? ?0?5. the first instalnient of an award of £40.1)00.00 for the work.. Targeting the adhesive fiinction5 itl intrahepatic CCA progression= focus on the cancer cell surface receptor5 engaged by the THBS l and THBS2 Universitv of LiveTpooI- AMMF Ref: 20231217 £1? $00.00 w'as paid otl ?? I? ?0?5. the fiT5t in5talment of an award of £25,000.00 for the work.. Interrogating tumour-mediated immunosuppre55ion in PEri-hilat CCA Henri MoNdor University Hospital- AMMF Ref: 20251229 £19.753.02 wa5 paid on 22.1? ?025. the fi1 in5taltnent of an award of £44,000.00 for the WOTk= Artificial Intelligence as a Biomarker for Inirahepaiic CCA Page 7
AMMF - The Cholangiocarcinoma Charity Trustees, Report AMMF'S External Collaboratio The charity is recogniLed Th'idel),. nationally and iniemaiionally. amongsi tM)th the generdl public and within medical circles. for its work in ihe field of CCA. and is (requenily invited to become part of Siudy groups and advisory boards. for example. Ihe w'orking group for Liver Transplantstion for CC.A, and the executive committee ofccA-UK. AMMF is also a member of ENS-CCA (European NeN'ork for the Study of CCA), an association of research groups from across Europe and bes'ond. activels oK.1ng on basic. translational. and clinical research in(0 CCA. and AMMF'S CEO is cfrchair of ihe ENS-CCA Paiient AdV(aCY Committee. The Global Cholangiocarcinoma Alliance IGCA) %as esthblished ar AMMF'S intemational workshop held in London in 018. The aim of ihe Alliwice is io pr()vide a uniied i'oice ihrough inieniational collaboraiion, rdise the global awareness of CCA and to improve ihe educaiion of both healthcare professionals and patients. Since the GCA'S incepiion in 018. AMMF has acied as rhe noi-for-profii partner in this venrure. and AMMF'S CEO Helen Moremeni is a CchaIr on the inicniaiional $eringY committce. During ?0•5. the role of secrerIal of ihe GCA and the orgyai)isation of the annual World Cholankiiocarcinoma Day in February.. Cholangyiocarcinoma A*'arencss Moi)th. passed from thc hcalthcarc communications agency AXON io Colab Healih who will now also manage the bespoke website and social media accounts. AMMF continues ¢0 be an aciiv¢ member of Cancer5? Ihe alliance of rdre and less common caiicer OTgTanisa¢ions in the UK, which provides Ihose 0janIzatIonS with a presence and a voice wiihii) every national cancer ini¢ialiYe. Ammk's CEO. Helcn MorLYn¢ni was apwinted a board diTectorltrustce of Cancer32 in 2014 and continued in that role until She resigned in AuL?ust 2025. Gallbljdder Guidelines and Dala Projcct- Professor Dhaiin), Gorn¢z of Notlinghwm University. the lead on th¢ new BSG IBriiish Sociely of tiasiro¢nlerologN') Guidelines for ¢h¢ Diagnosis and Mjnageineiil of Gallbladder Cancer. asked Hel¢n Moremenl. AMMF s CEO. to be pari of the leain preparing the guid¢line5, and for help in providing dala. As th¢r¢ was n(Tr separate robust dath for gallbladd¢r cancer. but AMMF s owii r¢c¢ntly ¢ompleted ond published data project for CCA had included the oiher biliary tract canc¢r% gallbladder canc¢r. ampullary anc¢r HDI IHealth Data Insight CIC) Mho prepared that work. were ask¢d by AMMF to provide a Stand-alon¢ d(Kurn¢nt on gallbladder canc¢r to 511PPOrt guidelines work". Th¢ dwum¢nt, 'F.pid¢miology and Treatment of (Jallbladder Canc¢r in England 20(Tr1 ?0?2. was prepared Imid ?0?5 aiid Submitted to the t¢am working on the gLiidelines. A5 at th¢ end of?0?5. work th¢ guid¢liiie5 was ongoing. Centres of Cholangi0¢8rcinom8 Experti5¢ Work on preparing a rationale for Centres of Cholangiocarcinoma Eipcrtisc. M hich bcoan in ?0?4. continued during the year. The steeriiig coniillittee, con51Sting of rncrnbers of CCA-UK and AMMF. decided that. based on the geogrdphical inequitie5 uncovered by AMMF'5 CCA data projecL a first step should be to explore ho. best to audit hospitals acr05S the UK to ascertain the number5 of CCA patients each wa5 seeing and what treattnent pathway5 were followed. SeveTal organisations M'ere approached to piovide a proposal at]d budget for undettaking thi5 M'ork. HDI (Health Data Insight CIC) w.ere selected for their knoM"led8e and experience in preparing and managing such an audit. and foi thcii c05tings. Reqiiests m.ere submitted to industry for nding to SUPPOrt this part of the Centres of Expert15e project. and AMMF agreed to act a5 secretariate and to manage the fi]nding aspect. This work was ongoing as a( year end. Page 8
AMMF - The Cholangiocarcinoma Charity Trustees, Report National Cancer Plan- AMMF submiiied evidence f(w ihe DHSC (Department of Health and Social Care} consultation April ?O?j. The submission available on AMMF'S websiie hltps.'//ammf.org.u2o2s/04lollShap1n8-lhentw-naII0na1wCartCer-p1a1 AMMF also participaied in two workshops with DHSC to further emphasise the charity's prioriiies.. In-person workshi)p beNeen DHSC and Cancer5? members in April ?025. • Virtual w'orkshop between DHSC and One Cancer Voice members in July 20?5. In August ?0?5. two of AMMF'S members joined One Cancer Voice (a Cancer Research UK initiative) outside Westminster. supw)rting the call for an ambiiious. funded National Cancer Plan. At ihe year end. publication of ihe Naiional Cancer Plan which had been expecred in November, was pushed back uniil early in ihe New Year. New therapv appr4i$als- During ?0?5. AMMF a5 inviied National Insiiruie for Care and Excellence INICCI to submit Mrittcii and ordl sialemciits iii support of the folloii'ing lic*, therapy apprai5als'. Zanidatarnab.. for thosc 1th an advanced HER-2 wTrsiiivc CCA. AMMF submittcd cvidci)cc for the apprdisal iii July ?0?5. This included commcnts from paticnts and iheir carcg?ivcrs wilh firsr_hai)d expericnce of zanidaiamab. and results from an online survey AMMF conducicd hleh achievcd 70 responses. Two AMMk' reprcscniaiivcs. noMinad io rcprcseni paiicnts. spoke ai the Cominittee Meetin on 09 December ?0•5. Ai the )'ear end, Ihe ouicome siill awaiied. Larotre¢tinib'. a largeled trealment for NTRK-fusion posilive solid tumours {approx 10/0 of CCA pati¥nlsl. AMMF submiiiLxl ¢vidcnce io the NICE apprdisal in Ociober 20?5. The appraisal Coinmittee Meeting 15 scheduled for March 20?6. External Evf nt5 A5 AMMF coniinued to expand its work ihroughoui ihe UK. into Europe and beyond, during 2025 the hari¢y Teceived a nuinber of invitalions to allend an(Vor to speak about CCA and the Charity's work at national and iiiteniational conferences including.. 17 Januar) 202$ EN&CCA I Precision BTC N¢tOrk (European Netw'ork for ihe Study CholAngiocarcinoma I Precision Biliar). Tract Cancer Nelmork) Heleti m0Ment gav¢ a pr¢senlatioii oil the various palienl r¢sourc¢s AMMF had joiiitly produc¢d with the Precision BTC N¢twork. . 2{22 Febru&ry 2025 EASL (Europcan Association for the Study of the Liver) Liier Cancer Surnmit. Paris. Helen Morement attended this meeting and gave a pre5entatioii oli the itnportance of the n)ultidisciplinary tearn in deciding treatment tyathwaJ'5 and the care of the CCA patient. Natasha Pite ai)d Sabita Maharaj, a metnber of AMMF s Clinical Nurse Advisor). BoariL a150 attendetL and Sabita spoke about her work a5 a nurse caring foi thosc with CCA. 10 March 2025 Cholangiobotics Project Conference and Launch ETrent. Nottingham UniveT5ity. Noel Cotri¥an. Chair of TTU5tee5. and Helen Moiement. CEO. attended to represent AMMF at the event launching thi5 project. Page 9
AMMF - The Cholangiocarcinoma Charity Trustees, Report I I April 2025 CholangiocarciThorna ConfereMce- IDterThational CoDseDSU5 Research Priorities Salt Lake Ciiy. USA. Helen Moremeni was inviied to be a Cowchair of the PatientslAdvocaies and Supportive Care Working Group la in 20?4. attending a number of preparatory. meeiings. and working with oihei advocates on a number of topics ro be presenied ai the Cholangiocarcinoma Foundaiion's annual conference ?0?5. During Ihe conference. Helen presenied on No topics re the CCA paiieni. Nuiriiion. and the ImpL)nance of ihe Clinical Nurse Specialisi. . 22-23 Mi)y 2025 Precision-BTL Net.ork Annual Meeting- Liquid Biopsy in Biliary Tract Cancer.. From Bench ro Bedside. Palma. Mallorca Helen Moremeni was a panel member in discussion group& and also presented ihe work of AMMF. • 08- 10 October 2025 Annual AUGIS. Scientifie Conference. (Jlasgow {' Associaiioii of Upper Gaslroiiiiesrinal Surgvery of Great Britain and Ireland) Heleii Morcmcni attcndcd to present on ihe topic: Thc successes and hardships of a cancer charity - the journey. 17- 111 November 2025 Astrazeneca Patient Advocacy Leaders. Sumrnit. Cambridge. UK Heliti Mor¥m¥nt alt¥nd¥d io r¥pr¥sL'ni AMMF ajid lh¢ CCA patienl in discussions and at various breakout meeting5 during the two day meetin& 01-02 Deccmber 2025 Ch0lanRiarel0rna-UK Annual Scicntific Mcetin2. Noitingham. Hellii MiirLmLni and AMMF s Paul 110i4.ard Oi¢LiidLxl Ihis meeiin¥. Helen 15 a member of the Executive Commi¢te¢ of CCA-UK. and look part in panel dis¢ussion$. 12- 13 Decembcr 2025 European Ad%'ocacy Groups Mc¢tinkL V¢nic¢. Italy At ihe invitaiion of Apic. Ihe Itolian palients. advocacy group. Helen Morement and Noel colgan attended the inaugyural meeting of k"uropeaJi advacy group5. Noel ¢haired the me¢tii)g and Heleii Morem¢nt presented th¢ work of AMMF. 22-24 January 2020 EA.SL (European Associa¢ion for the S¢udi of ¢he Liver) Lii'er Cancer Summit, Edinburgh. UK Heleii Morement atteiided this ineelin£ to cfrchair the Q&.A discus%ions fallolI1g th¢ plenary 5¢S5ion'. CCA and rare liver thmour5'. patho8enesis and tredtment. LOOKING TO 2020 Arnongst our planned events 111 - The Rethink Liver Cancer Campaign and Westrninster Reception 21126 The Rethink Liver Cancel catnpaign LS ongoing and ii.ill continue into ?0?6. especially during February's Cholangiocarcinoma AM'arene55 Month "ben we m.ill be holding a further reception in Westminster. iii the House of ComTnon5 Churchill Rootn. This event w.ill once again be hosted by Mary Glindon. MP for Newcastle upon Te East and Wallsend. We plan to launch 50tne new. powerful videos from patients and carers to ut]derlint the need for policy change. Page 10
AMMF - The Cholangiocarcinoma Charity Trustees, Report Centres of CholaNgiocarcinoma Expertise - The work on ihe hospithl audit will continue. The Ouome$ of ihe CCA data projeci and ihe publieation ofihe new" BSG Guidelines for the Diagnosis and Management of CCA gave AMMF the ammunition to begin w.ork towards building the case for Cenires of CCA Expertise. During ?0?5. a sieeiing group ofspeeialists in CCA. along wilh AMMF. has been working with HDI in planning and preparing a quesiionnaire for a hospitsl audit w ascertain ihe numbers of those diagnosed wilh CCA and the irvdiments ihey aciually receive. St is planned this audit should begin during AMMF'S European Cholan2iocareinoma Conftrenee 2026- The 20?6 conference .111 take place 13-15 Ma}, w'iih a global taculij and cfrchairs. Professor Brian Daiidson IUKI and Dr Angela Lamarca (Spainl. two intemationally renowied specialists ai the forefroni of the CCA world. AND FINALLY AMMTr has &Frown steadily over the years and. with ihe continued help of lol'al fundraisers and supponers. sponsors and advisors. we will coniinue our work and remain fully commilled ro achieving a far betier future for all those diagnosed with CCA. At thc heart of everything we do is the CCA palienr and iheir families, and each and every, day all of us at AMMF strive iowards thai impr()Ycd fuiure for all ihose diagnosed with this most challenL¥ing of cancers. AMMTr' will coniinuc lis work uniil ihai ¥yoal is reached. FINANCIAL RF.VIF.W Financial review and reitrvfs policy ThL Lharii} has coiitinuLd io SirLnlih¥n its financial position during the year. The charity ensures that sufficient reserves are relained in an appropriate fomi io fund its current obliLtations. Where Specific r¢se8rch proj¢¢ts hove been secured. Ihe iruslees designate sufficient unrestricted reserves to cover ihe expeci¢d full1 grants payoble over the term of th¢ research projecl. Structure, Governance and Management Goi'erning document The charity is ¢onlroll¢d by its governing documenL ond ¢imstituteS on in¢orpornt¢d charity. 2 No¥ember 2026 Approved by order of lh¢ board of iruslees on ................-............ and signed on its behalf by.. Noel Corrigan Noel Corrigan- Chair of Tru5tee5 Page 11
AMMF - The Cholangiocarcinoma Charity Independent Examiner's Report to the trustees of AMMF - The Cholangioeareinoma Charity I report io the chariry irusiees on my examinaiion of the accounts of the charity for the year ended 31 January 2026 which are set out on pages li 10 25. Responsibilities and basis of report As ihe chariiy's trustees you are responsible for ihe preparaiion of ihe accounts in accordance with the requirements ofthe Charities Aci 2011 ('the Ati.). I report in respect of my e%aminaiion of ihe chatilv s accounts eartied oui under section 145 of ihe Act and iii carrying out m> e.xamination I have followed all the applicable Dlretlions given b> ihe Charii>' Commission under seciion 145(5Xbl of the Aei. Independent examiner's statement Since the eharity's gross in¢om¢ ¢x¢¢eded £?50.(M)O your ¢xamin¢r must b¢ a memb¢r of a body listed ii) se¢tion 145 of the Act. I confirm thai l am qualified to undertake ihe elaminatioii b¢¢ouse l am a m¢mb¢r of the Ass(Kiation of Charter¢d CerlifL¢d Accountants. M'hich is on¢ orth¢ list¢d bodi¢s. I hav¢ ¢ompl¢t¢d my examination. l ¢onfim thot no mat¢rial matt¢ts hav¢ come to my atten¢ion in ¢oiinectioii with ihe examination giving me cause io believe that in any maierial respeci.. accounting records were noi kew in respect of the chariry as required by section 130 of the Act.. or the accounts do not accord wilh those records: or the accounts do rtot ¢ornply w'ith ih¢ applioable requirements ¢on¢eniin& ihe forim and ooiileiii of accoiints set out in the Charili¢s (Accounts and Report51 Regulaiions ?008 oth¢r ihan any r¢quireineiil that th¢ accounts giv¢ a 'tru¢ and fair vi¢* Mhich is iiot a niatt¢r consid¢red 95 parf of aii iiidep¢nd¢nl examination. I have no concerns and have come across no other matters in connection with the examination to which atteiitioi) should be drdwn in this repon in order io enable a proper undersianding ofihe accounts 10 be reached Sandra Morrell Sandra Morr¢ll FCCA 146 New London Road Chelmsford Essex CM2 OAW 3 November 2026
AMMF - The Cholangiocarcinoma Charity Statement of Financial Activities for the Year Ended 31 January 2026 (Ineluding Income and Expenditure Aeeount alld Other Comprehensive Ineome) Total 2020 Total 2n2> Unrestricted Restricted Note Income Endowments frojn: Donaiions and legacies Other trading activities Investment income 674,438 19.?00 ?1.85? 38?19 912,657 19.900 21.852 1,019.470 6.422 19.9?9 Total incom¢ 715,490 ?j8?19 95i.709 1,04.S.8?1 Expenditure on: Raising fiinds Charitable activities 9.608 584,378 9.608 995.993 2.703 818.729 411.615 Toial c¥penditure 593,986 411.615 1,005.601 8•1,43? Nei incomellexpenditurel Transfers between fLinds 117J.i96) 39.114 151,8921 ??4.389 139.114) Nei movement in funds (134,?82) 151,89?) ??4,389 Reconciliation of funds Total fLinds brou&h( fon¥ard Total funds ¢arri¢d forward 1.11? ?45 147.539 1 ?59.784 1.035.395 17 1.194.035 1 ?07.89? 1 ?fj9.784 All of the charity's activities derive from continuing operati(Trns during the above two periods. Page 13
AMMF - The Cholangiocarcinoma Charity {Registration number: CE028473) (Charity number: 1198095) Balanee Sheet as at 31 January 2026 2026 2025 Note Fixed assets Tangible assets 10 9.(M)I 7,783 Current assets Stocks Debtors 8.827 45.387 1,3?6.?36 9.839 12 Cash at bwik and in hand 13 1,394.776 1.380.450 1,489.902 Creditors: Amounts falling due wiihin on¢ Year 14 {181.559 ?37.901 Net current 855ets 1.198.891 ?5?.00 I Nel a55et5 1 ?07.89? 1 ?59.784 Funds of the ch4ri¢y: Restrictcd income fund5 Res¢ric¢ed funds 17 147.539 Unre5trieted income funds UnTe5tricted funds 1.194.635 1,11? ?45 Total funds 17 1 ?07.89) 1 ?59.784 The financial statements on pages 13 to 25 were approved by the trusiees. and authorised for issue on 2 November 2026 and signed on their behalf by.. Noel Corrigan Mr Noel Corrigan Chaimian Page 14
AMMF - The Cholangiocarcinoma Charity Statement of Cash Flows for the Year Ended 31 January 2026 2026 202S Note Cash flows from operating activities Net moveTnent in funds per SOFA (51.892) 2?4.389 Adjuslmenls D¢pr¢ciation Investment income 6.406 i.432 (19.929) (67.338) 207.892 Working capital adjustments Decrcasc,lincrcascl iii siocks Decreasellincreasel in debiors (Decreasellincrease in creditors IDecreasellinereas¢ in d¢ferred income 1.012 39.900 151.34?) 5.0001 13,?04) 115,654) 25,737 2.S.000 12 14 Nei cash flows from operating activilies 18? 768 ?39.771 Cash flows frum inve5¢ing 8clivi¢ie5 Int¢r¢st r¢ceivabl¢ and similar income Purchase of tangyible fixed assels ?1.857 7.6?4 19.929 6,996 10 Nei cash tlow's from invesling activilies Nei IdecTease Jlincrease in cash and cash equivalen15 168.5401 ?5? 704 Cash and cash equivalents al l February 1.394.776 1,14?.07? Cash and cash equiYalerb(s at 31 January 1.376.?36 1.394.776 All of the cash flows are derived from continuing operations durin8 the atmive two periods. Page 15
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 l Aeeountimg polities Statement of cornpliaDce The accounis {financial siaiemenis) have been pw)ared in accordance with the stsiement of Reeommended Practice." Accounting and Reporting by Charities preparing iheir aecounts in accordance M'ith (he Financial Reponing Siandard applicable in ihe UK and Republic of Ireland IFRS 102) issued on 16 July 2014 and ihe Financial Rerting Siandard applicable in ihe Uniied Kingdom and Republic of Ireland IFRS 10?) and ihe Chariiies Aci 201 l and UK Generally ACCepd Practice as li applies from l January 2019. The accounts Itinancial siaiemenisl have been prepared to give a 'inJe and fairf view and have depaned from ihe Chariiies (Aceounis and Rewrts} Regulaiions ?008 only io ihe required io provide a true and fair view,. 'I'his departure has involved folloii'ing Accouniing and RcrA)rting by Chariiics preparing their accounts in accordance wilh ihc Financial Rcwjrting Siandard applicable in ihe IJK and Rcpublic of Ircland IPRS IO Issucd 011 16 July 014 raihcr ihan ihe Accouniing and Rcponing bj. Chariiies.. Sthiement of Rccommcnded Practice effective from l April ?005 which has since been withdrawn. Basis of prepAration AMMI.- 'I'hL Cholanbiiocarcinoma Charity meets the definiiion ora public benefii eniity under FRS 102. Assets and liabilities are initially recogynised ai hisiorical cost or wdnsafflion value unless othenvi5e stated in the relevant accountin& policy noles. GoinE tothtern The irusiees consider thai there are no maierial uncenainiies aboui ihe chariij's abilit}, io continue as a g?oing concem nor any significanl areas of uncenainiy thai affeci the carrying value ofassets held by the chariiy. Ineome and endowmenis All incL7me is recognised once ihe charii). has entiilemeni io the income. il is probable that the income will be received and the amoun¢ of the income receivable can measured reliably. Donqliov.T lexq¢'ie.s Donation5 ar¢ re¢ognis¢d w'h¢n th¢ charity has beeli iiotifi¢d in writing of both th¢ amouiit and s¢ttl¢m¢nt date. In thc evcnt that a donation is subjcct to conditions that rcquire a Icvcl of performance b). thc cliaritv bcforc thc charity 15 Clltiilcd to the fund5. the income is dcfcrrcd and not rccogn15ed until cither thosc conditioi)s arc fully mct, or thc fuifilmcnt of those conditior15 is M'holly within thc control of the charity and il is probable tliat thcsc condition5 w'ill bc fulfilled in thc reporting period. Deferred Income Deferred income represents amounts received for fuiure per1JS and is released io incoming resources in the period for which. it has been received. Such income is only deferred when= The donor specifies thai the granl or donaiion musi only be used in fuiure accounting periods- or - The donor has Im[ed conditions which must be before the charity has uncondiiional entitlement. Inveslpnenl imrome Dividends are r¢cognised once the dividend h&5 been declared and notification has been received of the divid¢nd due. Page 16
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 Expenditure All expenditure is recognised once there is a legal or constrnctive obligaiion to that expenditure, it is probable senlement is required and ihe amount can be measured reliablv. All costs are allocaied to the applicable expenditure heading thai aggregate similar to ihai Cagory. Where costs cannot be direcily affributed t panicular headings they have been allocaied on a basis consisnI 1th the use of resources. 1[h central staff costs all(ated on the basis of lime spenL and depreciaiion charges all(KaTrd on the portion of ihe asset's use. Other siippon cosis are allocaied based on the spread of sthff costs. RalJingfund These are costs inciirred in attracting volunlary in¢orn¢. th¢ mona¥wn¢nl of inv¢stm¢nts and thos¢ incurrcd in trading activities that rais¢ fund5. Charilable deilvllles Chariiable expenditure comprises those costs incUed by the charity in the delivery ofits activiiies and services for ils beneficiaries. It includes both costs that can be allocaied directly io such activities and ihose cosis of an indireci nature necessary, (o support them. Governanc¢ ¢oslS Thesc iiicludc the costs ai(ributable io the charity's compliance with consiiiuiional and staiutory requirements. includinbi audit. straic&>ic manabpemeni and irusices mceiings and reimbursed cxpenses. Tangible fixed 85$¢¢$ Individiial fixed assets cos11n £50.00 or more are iniiially recorded at cost. less any subsequent accumulated deprccidtion and subsequeni accumulated impaimien( losses. Depreei#tion #nd 8rn0rt15alion Depreciation is provided on ian¥ible fixed ass$ so as io Wri oif the cost or valuaiion. less any estimaied residual value, over their expected useful economic life as follo$.. Asset class Compiiler equipment Deprecia¢ion rnethod and rate 33/0 Stock Stock 15 valued at the lower of cosi and estimated selling price less costs to complcte and sell. after due regard for obsolete and slow moving stocks. Cost 15 detcnnined using the fir5t-in. fLIStul {FIFO). Trade debtors Trade debtors are amounts due from cu5tom¢r5 for mcrchandi5e 501d or 5ervice5 pcrforn)ed in the ordinary ourse of busine5S. Trade debiors are recognised iniiially at the transaciion price. They are subsequently measured at amortised cost Using the eff¢ctive inieresi meihod. less provision for impaimieni. A proii5ion for the impairnient of trade debtors is established when there is objeeiive evidence tha( Ihe charit>. m.ill noi be able to colleci all amounts due according to the original temis of the receivables. Page 17
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 Cash and cash equivaleNt5 Cash and cash equivalents comprise cash on hand and call dewlts, and other short-ierni highly liquid invesiments thar are readily convertible io a knowi arnouni of cash and are subjeci to an insignificant risk of change in value. Trade creditors Trade crediiors are obligaii(FnS 10 pay for giKKis or services ihai have been acquired in ihe ordinary course of business from suppliers. Accounis payable are classified as curreni liabiliiies if ihe charity does noi have an unconditional right. at thc end of the re[ing riOd. io dcfcr scrtlcmcnt of the crcdiror for at least twelve months after thc reponing daic. If ihcre is ali uncondiiional righi ro defer settlement for ai least N'elve moiiths after the reponing date. Ihey arc prescnicd as non-curreni liabilirics. Tradc crcditor5 are rccogniscd initially ai the wansaciion price and subsequently measured at amortised cost using the effcctivc intcrcsi mcihod. Fund structure Unr¢stTicied income funds are generdl fund5 lh available for use at the Iruslces's discrelioii iii furtherance of the objectives of the charity. Res¢ric¢¢d income funds are those donaied for use in a particular oreo or for spe¢ifi¢ Purposes. Ihe use of which is restrieied to that area or purpose. Financial instruments Cla.i.¥l}IL'ftilon Financial assets and financial liabilities are re¢ognised when the charity becomes a party to the contractual provision5 of the instrument. Financial liabilitie5 and equity instruments are classified according io the substance of the contractual arrangements eniered into. An equity instrument is any contract that evidences a residual iniere5t ii) the a55et5 of the charity after deductin8 all of its liabilities. 2 Income from donation5 and le¢1¢$ Unrestricted fund5 Restricted fund5 Total fund5 Donations and legacies 674.438 ?38?19 91 ?.657 Tolal for 2020 674.438 ?38.19 91 ?.6.57 Total lor 2025 756.689 26) 781 1,019.470 Page 18
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 3 Income from other trading activilies Unrestricled funds Restricted Total funds Trading income". Shop incotne 19.?00 19,200 Total for 2026 19.200 Total for 2025 6.4?2 6.422 4 Investment incorne Unre51ricled fund5 Total fund5 Iniere5t receivable and similar income,. Interest receivable on bank deposits *1.851 1.85? Total for 2026 ?1.85? ?1.852 Total for 2025 19.929 19.9?9 S Expenditure on charitablc attiiities Vnre51rict¢d rund$ To141 2026 Tol¥l 2025 R¢stri¢t Note European Conference Costs 223.654 115.704 391.934 19.681 615.588 135.385 576.752 90.771 Grants to instiiutions Depreciation. amortisalion and other similar costs sta Losts Govemance costs 6.406 231.1?4 7.490 6.406 231.124 7.490 3.432 133.689 14,085 584.378 411.615 995.993 815.729 Page 19
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 6 Analysis of Rovernance and support eosts Governance cost5 Total 2026 Total Audit fees Audit of the financial staiemenis Ind¢p¢ndent ¢xwnin¢r f¢¢s Accounis and independent examination Payroll fees Bookeeping fees 1 ?.600 4.230 1.230 ?.030 284 7.490 14.085 7 Net incorningloutgoing resour£¢s Nei (ouigjoinsllincoming resources for ihe year include.. 2026 2025 Audit fees Depreciation of fiKed &%sets 6.406 3.43? 8 Trustees remuneration and expens No trustees. nor any persons connected with them. have received any remuneration from the charity durinb the year. During the year. £1,410 in expenses were reimbursed to 4 Trustees (2025.. £4.784 to 4 Trustees }. 9 Staff costs The aggregate pa>'roll costs We follow5.. 2026 2025 Staff cost5 during the year were: Wage5 salaries Social security costs Pension costs 208,996 17,390 4.738 123,528 7,796 2.365 231.1?4 li3,689
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 The monthly average number of persons (including senior managemeni I leadership team) employed by the charity during the year expressed by head count m.as as folloii"s= 2026 No 2025 No Employees No employee received emoluments of more ihan £60.000 during the year. Th¢ totpl ¢mploy¢¢ b¢n¢fits of th¢ k¢y tn8n¥g¢m¢nt p¢rsonn¢l of th¢ charity w¢r¢ £60.7911?025- £52.4631 10 Tangible fixed assets Computer equipment Total Cost Ai l February ?025 Additions 16.449 7.674 16.449 Ai 31 January ?026 ?4.073 ?4.073 tkpr¢¢ialion Ai l F¢bruary ?025 Charge for ¢he year 8.666 6.406 8.666 6.406 At 31 January ?026 15.07? 15.07? Net book value At 31 January 2026 9.001 9.001 At 31 January 2025 7.783 7.783 I I Stoek 2026 Stocks 8.8?7 9.839 12 Debtor5 2026 2025 Trade debtors Prepaytnent5 Accrued income 18.800 3?.960 12,208 45,387
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 13 Cagh and eash equivalenis 2026 2025 Cash on hand Cash at bank 193 1.3?6.(H J 202 1,394,574 1,3*6.936 1,394.776 14 Creditors: amounts falling due within one year 2026 2025 Trade creditors Accruals for biranis Other taxation and social security A¢¢ruals D¢ferr¢d income 39.180 10• 527 5.701 13.394 168.938 3.945 26.624 ?.s.000 0.000 181.559 937.901 2026 2025 tkferred in¢ome 01 l Febntary ?025 Resources deferred in the period Amounts released from previous periods Deferred income ai year end ?5.(M)O ?O.(M)O !5.000 25.000 ?0.000 25.000 Included wiihin deferr¢d income for 20?6 is £?O.(MIO for sponsorship for th¢ 20?6 AMMF Conf¢reii¢e. 15 Obligations under leases and hire purchase contraets The total value of future minimum lease payments was as follows.. 2026 2025 Wiihin one year In two to five years In over five years 43.116 7?.939 954 27.276 34.689 4.770 17,009 66,735 16 Contingent liabilitie5 At 31 January 2026 grdnts of £490.864 {20?5= £161.999) had been aw7rded of which conditions for the recognition in the year had not been met.
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 17 Funds CMrreNiyedr.' Balance al I February 2025 Balance at 31 January 2026 Incoming r¢source5 Resources exptnded TraDsfers Unre.flricledfund.f Cicncral Funds 715,490 (593,986} li9,114) 1.194.635 Restrieted Restricted Research Funds European Websiie Project External Projects {19,681} 13,257 77.848 86.7.$3 127.848) 66.96? ?38.?19 1391.934 Total rrslricled 147.ii9 ?38.?19 i9.114 Total funds 1 ?5¢4.784 953.709 { I.LNJ5.601 } 1 ?07.89! Prlur J'ear.. Balanee at Ftbruary 2024 Balanc¢ at 31 .lanuary Incoming resources Resourees expended Transfers Unrestricied funds Unre.Tlricledfund.$ (iLiicral Fuiid. 954,799 783.040 {518.7941 (106.800) 1,112,245 Restricted Restricted R¢seaTch Funds European Websile Project European Conference 2024 External Projecis 21,120 23.606 11.818 32.938 27.848 (7581 {?47.7631 (54.117 140,963 105.1KJO 106,800 35.870 86.753 Total restricted funds 80.596 ?6? 781 30?.638 106.800 147..539 Total fund5 1.035.395 1.045.8?1 18?1.43? 1 ?59.784
AMMF - The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2026 The specific purposes for which the funds are io be applied are as folloH's.' Restricted research funds represent donaiions Mheie the donor has re4uesied ihai their donation be used for research purposes onl>. These donations are held wiihin resiritied funds until utilised in part or in whole io fund a cholangiocarcinoma researth projeei which the charily has commiiied io support. Restricted funds for each of ihe major projects AMMF undertakes represent those donations or sponsorships here ihe donor has requested that their monies be used for ihai panicular projeci only. Those funds are held as resiricied funds uniil used in full or in part 10 compleie ihe project for which they were given. Restricted tunds for the major. exiemal projects AMMF undertakes represeni sponsorships 10 guppon only those individual specific projects for which the funding has bccii given. The number of such projects varies from year to year. The transfer of £39,114 represents restricted projects and events funded from unrestricted funds due ro a shortfall in funding received. 18 Analy$i5 of net a55e15 between funds Total funds at 31 January Unmirieied funds Restricted fund% 2026 Tangible fixed asse¢s cuent assels Current liabilities 9.(M) I 1.367.193 181.559 9.001 1.380.450 181,559) Total nei assets 1.194.635 1 ?07.89? Total funds at 31 January Unre5trieted funds Restricted rund5 Tanbjible fixed assets CUCt asscts Current liabilities 7.783 1.34?.363 ?37.YOI 7.783 1.489.902 {?37.YO I 147.539 Total net assets 147.539 1759.784 19 Related party tran5aCti0115 There were no related party transaciions in the year.